Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma: The SAVOIR Phase 3 Randomized Clinical Trial

In this Phase III study (n=60; stopped early), there was no statistically significant difference in progression-free survival between savolitinib and sunitinib (7.0 months [95% CI 2.8-not calculated] vs. 5.6 months [95% CI, 4.1-6.9]; HR 0.71; 95% CI, 0.37-1.36; P=0.31).

SPS commentary:

Recruitment into this study was stopped prematurely because the results of a concurrent retrospective molecular epidemiology study on the outcomes of patients with MET-driven papillary renal cell carcinoma receiving treatment with sunitinib suggested MET-driven status did not appear to be a negative predictive factor for treatment outcomes. It was therefore concluded that the trial would be unlikely to detect a difference in efficacy between the treatment groups.

JAMA Oncology